Extended Data Fig. 9: Evaluation of NETMAP-mediated anti-tumor effects in an orthotopic CT26 colon tumor mouse model.
From: Engineered bacteria for near-infrared light-inducible expression of cancer therapeutics
a, Schematic illustrating the experimental procedure and schedule for assessing the colonization performance of ΔXIV-lux in the orthotopic CT26 colon tumor mouse model. Wild-type (WT) BALB/c mice and BALB/c mice bearing orthotopic CT26 tumors were intraperitoneally injected with ΔXIV-lux (100 μL, 5 × 106 c.f.u.) on Day 0. b, The bioluminescence signal intensity from ΔXIV-lux was quantified with an in vivo imaging system on Days 0, 2, 4, and 7 after bacteria injection (n = 5 mice per group). c, Bioluminescence signal quantification from ΔXIV-lux in b. d, Schematic illustrating the experimental procedure and schedule for evaluating the anti-tumor performance of ΔXIVPadC4-NETMAPAzurin+ClyA against the orthotopic CT26 colon tumor mouse model. e, Bioluminescence imaging of mice bearing orthotopic CT26 colon tumors expressing luciferase (n = 5 mice per group). f, Bioluminescence quantification of mice in panel e. g, Kaplan-Meier curves for mouse survival in the indicated mouse groups for 20 days. Data (c, f, g) are presented as means ± s.e.m., n = 5 mice per group. Statistical analyses in c, f were performed using two-way ANOVA followed by Sidak’s test with multiple comparisons. Statistical analyses in g were performed using the Log-rank (Mantel-Cox) test.
